Julie M. Vose, MD, MBA

Julie M. Vose, MD, MBA, professor of internal medicine and chief of the division of oncology & hematology at the University of Nebraska Medical Center, discusses the importance of conducting genetic testing on all patients with diffuse large B-cell lymphoma (DLBCL) to better understand their disease and treat the disease properly.

Videos

Julie M. Vose, MD, MBA, discusses the importance of conducting genetic testing on all patients with diffuse large B-cell lymphoma to better understand their disease and treat the disease properly.

Rationale for Genetic Testing in Patients With DLBCL

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.

Julie M. Vose, MD, MBA, discusses resistance to BTK inhibitors in patients with non-Hodgkin lymphoma.

Overcoming BTK Inhibitor Resistance in NHL

Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference.

While many patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, are able to be cured, there are still many patients that cannot be cured, and the reason is still unclear, Vose explains.

Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference.&nbsp;

Julie M. Vose, MD, MBA | Authors

Articles

Rationale for Genetic Testing in Patients With DLBCL

Overcoming BTK Inhibitor Resistance in NHL

Exploring Novel Agents to Target Pathways in Lymphoma